ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Targeting prostate adenocarcinoma tumor microenvironment via cancer nanotheranostics: a comprehensive update on improved roadmap for disease diagnosis, therapy and management.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Prostate adenocarcinoma (PAC) ranks second as most lethal malignancy in men worldwide with significant economic burden on public health management. Despite of cytoreductive surgery of visible tumor mass followed by administration of chemotherapies including androgen deprivation therapy (ADT) using several drugs including enzalutamide, patients develop therapy resistance displaying metastatic, castration-resistant PAC (mCRPC). Furthermore, mCRPC patients fail to respond to neoadjuvant chemotherapies (NACT) such as androgen receptor-targeted agents (ARTAs) and develop a lethal, highly aggressive, therapy-induced neuroendocrine PAC (NEPC). Hence, identification of novel, targetable drivers and therapeutic interventions are highly warranted to manage this lethal pathology. Recently, nanotheranostics, an approach combining cancer diagnostics and therapeutics via nanotechnology is emerging as a promising intervention strategy towards early detection, disease remission and improved PAC patient survival outcomes. It frequently targets interacting components between cancer cells and tumor microenvironment (TME) which play critical role in disease progression and chemoresistance. For example, multimodal peptide-based imaging probes (peptides complexed with Cu
Indexed as
Identifiers
41258335What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.